Blood transcriptional profile changes and the presence of a novel cell type – termed PRIME cells – may be indicative of an impending flare in patients with rheumatoid arthritis, suggest findings from a longitudinal genomic analysis published in TheNew England Journal of Medicine.
Add-on treatment with an IL-6 receptor inhibitor warrants further investigation for patients with severe COVID-19 pneumonia and systemic hyperinflammation, suggest preliminary findings from two Italian observational studies published in the Annals of the Rheumatic Diseases.
Some patients with rheumatoid arthritis continue to experience residual symptoms despite achieving treat-to-target goals, but there is a paucity of evidence on the exact prevalence of these symptoms and their impact, report the authors of a systematic review.
A large UK study using the OpenSAFELY analytics platform has identified autoinflammatory diseases including rheumatoid arthritis and systemic lupus erythematosus as possible risk factors for COVID-19-related death.
A smartphone-based pain self-management program – iCanCope with Pain – warrants further investigation in adolescents with juvenile idiopathic arthritis following a successful pilot trial, researchers report.
A systematic review and network meta-analysis finds few significant differences in the benefits and harms associated with different biologics when given in combination with methotrexate for the treatment of rheumatoid arthritis.
Treatment with the JAK inhibitor upadacitinib leads to significantly better clinical and radiographic outcomes than methotrexate therapy among patients with moderate-to-severe rheumatoid arthritis who have no or limited prior methotrexate exposure, show the SELECT-EARLY results.
Different subsets of macrophages in the synovial tissue could help predict whether patients with rheumatoid arthritis will experience flares following treatment discontinuation, researchers report in Nature Medicine.
Preliminary findings from the GRECCO-19 trial suggest that colchicine, an anti-inflammatory drug used in the treatment of gout and familial Mediterranean fever, may have potential as a therapeutic agent for COVID-19.
The likelihood of experiencing an adverse event after initiating treatment with a first biologic DMARD increases with age and is higher in women than men, show data from a real-world study among people with rheumatic diseases.
Diacerein has comparable efficacy to celecoxib for pain reduction in patients with moderate-to-severe symptomatic knee osteoarthritis and is well tolerated, suggest study findings reported in Rheumatology.